融合蛋白抗肿瘤 z-bo 2020-12-18 589

　　Objective To investigate the anti-tumor effect of fusion protein I30 peptide and provide experimental support for the subsequent development of I30 peptide.

　　 Method Using NIH mice, 4 mice were intraperitoneally injected with H22 tumor strain, and all mice were sacrificed at 1 week, and ascites were taken. Another 40 mice were taken, and 0.2 mL of ascites was injected into each armpit, and the cell concentration was 1×106 cells/mL. The administration started 4 hours after vaccination. The axillary injection mice were randomly divided into 4 groups: IFN group, subcutaneous injection of interferon 9x105IU/mouse; I30 high-dose group, subcutaneous injection I30 80 μg/mouse; I30 low-dose group, subcutaneous injection I30 30 μg/mouse; negative control In the group, an equal volume of saline was injected subcutaneously. Continuous administration for 16 days. 2h after stopping the drug, all animals were sacrificed, and the subcutaneous tumor masses were dissected and weighed.

　　 Results The I30 administration group has a significant therapeutic effect, and there is a significant difference (P<0.05).

　　 Conclusion I30 peptide has anti-tumor effect.